首页> 外国专利> Antibodies, antibody fragments and antibody derivatives that bind specifically insulin-like growth factor-I receptor and inhibit the cellular activity of the receptor by antagonizing the receptor

Antibodies, antibody fragments and antibody derivatives that bind specifically insulin-like growth factor-I receptor and inhibit the cellular activity of the receptor by antagonizing the receptor

机译:特异性结合胰岛素样生长因子-I受体并通过拮抗受体抑制细胞活性的抗体,抗体片段和抗体衍生物

摘要

Disclosed herein are antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of same with cytotoxic agents, which specifically bind to, and inhibit, insulin-like growth factor-I receptor, antagonize the effects of IGF-I, IGF-II and serum on the growth and survival of tumor cells, and which are substantially devoid of agonist activity. Said antibodies and fragments thereof may be used in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, prostate cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer, and said derivatized antibodies may be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.
机译:本文公开的是抗体,人源化抗体,表面抗体,抗体片段,衍生化抗体及其与细胞毒剂的结合物,它们特异性结合并抑制胰岛素样生长因子-I受体,拮抗IGF-I的作用, IGF-II和血清对肿瘤细胞的生长和存活,并基本上没有激动剂活性。所述抗体及其片段可用于治疗表达IGF-1受体水平升高的肿瘤,例如乳腺癌,结肠癌,肺癌,前列腺癌,卵巢癌,滑膜肉瘤和胰腺癌,以及所述衍生抗体可以用于表达IGF-I受体水平升高的肿瘤的诊断和成像。

著录项

  • 公开/公告号NZ536479A

    专利类型

  • 公开/公告日2008-06-30

    原文格式PDF

  • 申请/专利权人 IMMUNOGEN INC.;

    申请/专利号NZ20030536479

  • 申请日2003-06-12

  • 分类号A61K39/395;C07K16/28;

  • 国家 NZ

  • 入库时间 2022-08-21 20:06:39

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号